What are RBC’s Top Pharma Stocks
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Merck & Company Inc (MRK)
Find all the information about Merck stock. Discover our multiple sections with data on Merck share price, intuitive charts, historical data, technical analysis, latest news on Merck shares and more. Find quotes of MRK in the main stock markets such as NYSE and London, among others.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
119.00
122.50
52 wk Range
73.31
125.14
MRK is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
119.00122.50
52 wk Range
73.31125.14
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.85%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.85%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MRK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
126.57
Upside
+6.05%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 15 consecutive years
- FDA approves Merck’s NUMELVI for dog skin allergies
- Investing.com
- What are RBC’s Top Pharma Stocks
- Investing.com
- FDA approves Merck’s NUMELVI for dog skin allergies
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Merck & Company Inc Company Profile
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck & Company Inc SWOT Analysis
Keytruda's Dominance | Merck's flagship cancer drug Keytruda continues to drive strong sales growth, beating expectations and maintaining market leadership in oncology |
Pipeline Potential | Explore Merck's promising developments in antibody-drug conjugates and KRAS inhibitors, poised to potentially offset future revenue challenges |
Market Challenges | Delve into Merck's strategies to navigate Keytruda's 2028 patent expiration, fierce oncology competition, and regulatory uncertainties |
Financial Outlook | Analyst price targets range from $84 to $145, reflecting varied perspectives on Merck's ability to maintain growth amid product transitions |
Merck & Company Inc Earnings Call Summary for Q3/2025
- Merck Q3 2025 EPS of $2.58 exceeded forecasts by 9.79%, with revenue of $17.28 billion beating expectations despite a 2.24% pre-market stock decline.
- KEYTRUDA sales increased 8% to $8.1 billion, driving overall performance, while GARDASIL sales decreased by 25% excluding China.
- Full-year 2025 guidance projects revenue between $64.5-$65.0 billion (1-2% growth) and EPS between $8.93-$8.98.
- CEO Rob Davis highlighted Merck's robust pipeline with approximately 80 Phase III trials and significant investments in new product launches.
- Management identified key challenges including loss of exclusivity, generic competition, potential drug pricing regulations, and increasing operating expenses in 2026.
Last Updated: 31/10/2025, 02:28 am
Read Full TranscriptCompare MRK to Peers and Sector
Metrics to compare | MRK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRKPeersSector | |
|---|---|---|---|---|
P/E Ratio | 16.6x | 19.1x | −0.6x | |
PEG Ratio | 2.02 | 1.17 | 0.00 | |
Price/Book | 5.8x | 1.6x | 2.6x | |
Price / LTM Sales | 4.7x | 2.3x | 3.3x | |
Upside (Analyst Target) | 8.9% | 0.0% | 44.5% | |
Fair Value Upside | Unlock | 29.3% | 5.0% | Unlock |
Analyst Ratings
18 Buy
12 Hold
0 Sell
Ratings:
30 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 126.57
(+6.05% Upside)
Earnings
Latest Release
Feb 03, 2026
EPS / Forecast
2.04 / 2.04
Revenue / Forecast
16.40B / 16.18B
People Also Watch
FAQ
What Is the Merck&Co (MRK) Stock Price Today?
The Merck&Co stock price today is 119.35 USD.
What Stock Exchange Does Merck&Co Trade On?
Merck&Co is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Merck&Co?
The stock symbol for Merck&Co is "MRK."
Does Merck&Co Pay Dividends? What’s The Current Dividend Yield?
The Merck&Co dividend yield is 2.85%.
What Is the Merck&Co Market Cap?
As of today, Merck&Co market cap is 295.15B USD.
What Is Merck&Co's Earnings Per Share (TTM)?
The Merck&Co EPS (TTM) is 7.30.
When Is the Next Merck&Co Earnings Date?
Merck&Co will release its next earnings report on 30/04/2026.
From a Technical Analysis Perspective, Is MRK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Merck&Co Stock Split?
Merck&Co has split 5 times.
How Many Employees Does Merck&Co Have?
Merck&Co has 74000 employees.
What is the current trading status of Merck&Co (MRK)?
As of 27/02/2026, Merck&Co (MRK) is trading at a price of 119.35 USD, with a previous close of 122.46 USD. The stock has fluctuated within a day range of 119.00 USD to 122.50 USD, while its 52-week range spans from 73.31 USD to 125.14 USD.
What Is Merck&Co (MRK) Price Target According to Analysts?
The average 12-month price target for Merck&Co is 126.57 USD, with a high estimate of 150 USD and a low estimate of 100 USD. 18 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +6.05% Upside potential.
What Is the MRK Premarket Price?
MRK's last pre-market stock price is 122.62 USD. The pre-market share volume is 7,450.00, and the stock has decreased by 0.16, or 0.13%.
What Is the MRK After Hours Price?
MRK's last after hours stock price is 119.63 USD, the stock has decreased by 0.33, or 0.28%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.